RxDoctor Payments DataLook up a doctor →

Mohsen Hamza, MD

Neurology with Special Qualifications in Child Neurology · Los Angeles, CANPI 1003996844

Payments from drug & device makers

$23,836in general payments, 2019–2025

Across 1,087 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • SK Life Science, Inc.$1K
  • MDD US Operations, LLC$1K
  • Amgen$906
  • Lilly USA, LLC$679
  • Biogen$671
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)281$6,185
SK Life Science, Inc.49$1,369
MDD US Operations, LLC138$1,348
Amgen(2 entities)45$906
Lilly USA, LLC28$679
Biogen33$671
Harmony Biosciences LLC29$667
Lundbeck LLC28$657
Argenx US, Inc.22$649
UCB, Inc.24$602
Sanofi22$600
Merz Pharmaceuticals, LLC18$577
Eisai Inc.24$523
Takeda Pharmaceuticals U.S.A., Inc.20$507
Kyowa Kirin, Inc.18$493
Acadia Pharmaceuticals Inc15$434
Neurelis, Inc.15$419
Amneal Pharmaceuticals LLC18$407
Axsome Therapeutics, Inc.9$384
Supernus Pharmaceuticals, Inc.19$337
AstraZeneca(2 entities)18$327
Pfizer12$323
CSL Behring12$310
EMD Serono, Inc.11$294
Sumitomo Pharma America, Inc.11$277
Tanabe Pharma America, Inc.13$277
Biohaven Pharmaceuticals, Inc.21$266
Medtronic4$265
Jazz Pharmaceuticals Inc.6$240
Acorda Therapeutics, Inc9$203
Merz North America, Inc.6$191
Mallinckrodt Hospital Products Inc.5$176
Teva Pharmaceuticals USA, Inc.7$175
Avadel CNS Pharmaceuticals, LLC5$165
Forte Bio-pharma LLC11$151
Corium, LLC6$135
SPR Therapeutics, Inc1$134
Biohaven Pharmaceutical Holding Company Ltd.11$130
Genentech USA, Inc.4$113
Abbott5$106
Catalyst Pharmaceuticals, Inc.4$96
Revance Therapeutics, Inc.3$95
Aquestive Therapeutics, Inc.4$75
Bristol Myers Squibb3$73
Immedica Pharma US, Inc.2$71
Avanir Pharmaceuticals, Inc.4$68
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$68
Springworks Therapeutics, Inc.2$59
Banner Life Sciences, LLC2$54
Idorsia Pharmaceuticals US Inc3$48
Electronic Waveform Lab, Inc.4$45
Novo Nordisk1$34
Zyla Life Sciences, Inc.2$31
Otsuka America Pharmaceutical, Inc.1$28
Octapharma USA, Inc.1$26
Sanofi-aventis U.S. LLC1$25
Livanova USA, Inc.1$25
E.r. Squibb & Sons, L.L.C.1$25
Azurity Pharmaceuticals, Inc.1$24
Metacel Pharmaceuticals LLC1$23

How this compares

$23,836 in reported general payments places this provider in the 70th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California →

Medicare billing

Part B allowed, 2024
$676,981
Medicare patients
186
Services billed
41,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →